arrow
F

Franco Nolè

European Institute of Oncology IRCCS
H指数:49
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world comparative outcomes of first-line immune combinations (ICI–ICI vs ICI–TKI) in metastatic renal cell carcinoma with sarcomatoid features

晚期肉瘤样特征性肾细胞癌中一线免疫联合疗法(ICI–ICI vs ICI–TKI)的实世界比较结果

2026-10-220
OA
Alkaline Phosphatase and Prostate-specific Antigen Response in Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide Alone or in Combination with Radium-223: Ad Hoc Analysis of the PEACE-3 Consortium Trial

碱性磷酸酶和前列腺特异性抗原在转移性去势抵抗性前列腺癌中,经恩扎卢胺单药或联合镭-223治疗后的反应:PEACE-3联盟试验的临时分析

2026-08-280
OAAI
Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.

EORTC 1333/PEACE-3试验的恩扎鲁他胺加镭-223治疗转移性去势抵抗性前列腺癌的最终总生存期结果。

2026-02-260
OAAI
Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial

恩扎卢替胺联合镭-223治疗转移性去势抵抗性前列腺癌:EORTC 1333/PEACE-3试验结果

2025-05-300
OAAI
Advancing breast cancer therapy in the era of molecular diagnostics

分子诊断时代下乳腺癌疗法的进展

2025-05-080
OAAI
Avelumab D axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial

avelumab联合达沙替尼与舒尼替尼作为晚期肾细胞癌患者的一线治疗:JAVELIN Renal 101 III期试验的最终分析

2024-12-013
PRE
A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3

一项随机多中心开放标签III期试验,比较无症状或轻度症状的去势抵抗性前列腺癌 (mCRPC) 患者的恩扎鲁他胺与镭223 (Ra223) 和恩扎鲁他胺的组合: eortc-gucg 1333/PEACE-3的初步结果

2024-09-0111
PRE
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 study

mRCC骨转移患者的钠水平和免疫治疗功效: Meet-Uro 15研究的子分析

2024-07-055
OAAI
Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial

奥拉帕利加阿比曲酮治疗转移性去势抵抗性前列腺癌: 来自PROpel试验的药代动力学数据

2024-04-011
OA
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study

接受nivolumab治疗的转移性肾细胞癌患者的策略失败和治疗超过进展的时间: 对Meet-URO 15研究的事后分析

2024-02-121
OAAI
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study
2023-07-013
OAAI
Safety analysis after 11 years of follow-up of the randomized phase III trial SAKK22/99: upfront chemotherapy in advanced HER2 positive breast cancer
2023-03-010
PRE
Rucaparib or Physician's Choice in Metastatic Prostate Cancer

Rucaparib或医生在转移性前列腺癌中的选择

2023-02-23161
OA
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication

在意大利的同情使用计划中接受伊匹单抗和纳武单抗治疗的转移性肾细胞癌患者的伴随药物预后评分: 简要交流

2022-11-043
OAAI
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study

先前的肾切除术在接受免疫治疗的转移性肾细胞癌中的预后价值: 对Meet-URO 15研究的子分析

2022-09-3011
OAAI
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
2022-09-2311
OAAI
Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study
2022-03-0165
PRE
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

多西他赛和泼尼松联合或不联合恩扎鲁他胺作为转移性去势抵抗性前列腺癌患者的一线治疗: CHEIRON,一项随机II期试验

2021-09-019
PRE